cis-Dichlorodiammineplatinum(II) and DTIC in malignant melanoma. 1979

C P Karakousis, and E P Getaz, and S Bjornsson, and E S Henderson, and M Irequi, and L Martinez, and J Ospina, and J Cavins, and H Preisler, and E Holyoke, and O Holtermann

Twenty-nine patients with advanced malignant melanoma were randomized to receive DTIC at a dose of 200 mg/m2 iv on Days 1-5 and cis-dichlorodiammine-platinum(II) at a dose of 40 mg/m2 iv on Days 1 and 4, repeated every 4 weeks (group A), or the same drugs plus procarbazine at a dose of 75 mg/m2 orally daily on Days 1-8 and vincristine at a dose of 1.4 mg/m2 iv on Day 1 (group B). These drugs were generally well-tolerated, but five of 16 patients in group A and six of 13 patients in group B required dose modification for either hematologic or renal toxicity. There were six objective responses among 16 patients in group A including one complete regression, while there were two objective responses among 13 patients in group B.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011344 Procarbazine An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. Matulane,Natulan,Procarbazine Hydrochloride,Procarbazine Monohydrobromide,Procarbazine Monohydrochloride,Hydrochloride, Procarbazine,Monohydrobromide, Procarbazine,Monohydrochloride, Procarbazine
D012075 Remission, Spontaneous A spontaneous diminution or abatement of a disease over time, without formal treatment. Spontaneous Healing,Spontaneous Regression,Spontaneous Remission,Healing, Spontaneous,Regression, Spontaneous,Spontaneous Healings,Spontaneous Regressions
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003606 Dacarbazine An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564) DTIC,5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide,Biocarbazine,DIC,DTIC-Dome,Decarbazine,Deticene,Dimethyl Imidazole Carboxamide,Dimethyl Triazeno Imidazole Carboxamide,ICDT,NSC-45388,Carboxamide, Dimethyl Imidazole,DTIC Dome,DTICDome,Imidazole Carboxamide, Dimethyl,NSC 45388,NSC45388

Related Publications

C P Karakousis, and E P Getaz, and S Bjornsson, and E S Henderson, and M Irequi, and L Martinez, and J Ospina, and J Cavins, and H Preisler, and E Holyoke, and O Holtermann
January 1979, Cancer treatment reports,
C P Karakousis, and E P Getaz, and S Bjornsson, and E S Henderson, and M Irequi, and L Martinez, and J Ospina, and J Cavins, and H Preisler, and E Holyoke, and O Holtermann
January 1978, Cancer treatment reports,
C P Karakousis, and E P Getaz, and S Bjornsson, and E S Henderson, and M Irequi, and L Martinez, and J Ospina, and J Cavins, and H Preisler, and E Holyoke, and O Holtermann
January 1980, Journal of cancer research and clinical oncology,
C P Karakousis, and E P Getaz, and S Bjornsson, and E S Henderson, and M Irequi, and L Martinez, and J Ospina, and J Cavins, and H Preisler, and E Holyoke, and O Holtermann
March 1979, Cancer treatment reports,
C P Karakousis, and E P Getaz, and S Bjornsson, and E S Henderson, and M Irequi, and L Martinez, and J Ospina, and J Cavins, and H Preisler, and E Holyoke, and O Holtermann
May 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
C P Karakousis, and E P Getaz, and S Bjornsson, and E S Henderson, and M Irequi, and L Martinez, and J Ospina, and J Cavins, and H Preisler, and E Holyoke, and O Holtermann
May 1976, Drug and therapeutics bulletin,
C P Karakousis, and E P Getaz, and S Bjornsson, and E S Henderson, and M Irequi, and L Martinez, and J Ospina, and J Cavins, and H Preisler, and E Holyoke, and O Holtermann
April 1979, Cancer treatment reports,
C P Karakousis, and E P Getaz, and S Bjornsson, and E S Henderson, and M Irequi, and L Martinez, and J Ospina, and J Cavins, and H Preisler, and E Holyoke, and O Holtermann
January 1979, Cancer treatment reports,
C P Karakousis, and E P Getaz, and S Bjornsson, and E S Henderson, and M Irequi, and L Martinez, and J Ospina, and J Cavins, and H Preisler, and E Holyoke, and O Holtermann
April 1982, Gan to kagaku ryoho. Cancer & chemotherapy,
C P Karakousis, and E P Getaz, and S Bjornsson, and E S Henderson, and M Irequi, and L Martinez, and J Ospina, and J Cavins, and H Preisler, and E Holyoke, and O Holtermann
January 1979, Cancer treatment reports,
Copied contents to your clipboard!